CERS 株価分析 — Cerus Corporation (Healthcare >> Medical Devices)
CERS に関するよくある質問
CERSのPER(株価収益率)は?
Cerus Corporation(CERS)は現在PER -22,066.98倍で取引されています。
CERSのROE(自己資本利益率)は?
Cerus CorporationのROEは-9.69%です。
CERSの配当利回りは?
Cerus Corporationの配当利回りは0.00%です。
CERSの品質スコア(Quality Score)は?
当社のAIはCERSの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CERSは今が買い時ですか?
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CERSはどのセクターに属しますか?
Cerus CorporationはHealthcare >> Medical Devicesセクターに分類されます(NASDAQ市場)
CERS AI Analysis Summary
Our AI summary for CERS: Cerus Corporation (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of -22,066.98, ROE of -9.69%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.27
Price
0.08
(3.65%)
Day Change
|
|
|---|
CERS, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.27 |
| PBV / Sector |
6.24 / 4.62
|
| Earning Per Share | -0.03 |
| PE / Sector |
N/A / 32.46
|
| PEG or PE/Growth / Sector |
757.27 / 0.50
|
| Average 1M Daily Value |
7.05 M
|
| Average 1W Daily Value |
10.79 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:47 |
| Symbol | CERS |
| Name | CERUS CORPORATION |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 201.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 441.34 / 20,302.66 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1220 Concord Avenue, Concord, CA, United States, 94520
Phone: 925 288 6000
Website: https://www.cerus.com
Employees: 261
Sector: Healthcare >> Medical Devices
Description: Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
Google